showed that the binding of ALDOC to GSK-β leads to the β-Catenin complex collapse and destruction, thus increasing cytoplasmic and nuclear levels of β-catenin in patients with non-small-cell lung cancer (35). The gene discussed is ALDOC; the disease is non-small cell lung carcinoma.